Parion Sciences Awarded Best Late Stage Product Development Company

The Best Late Stage Product Development Company Award was recently granted to Parion Sciences by the Triangle Business Journal and accounting firm BDO. The company, which is focused on creating novel therapies for both pulmonary and ocular medical conditions, was presented with the award at an event in Cary, North Carolina, and is part of the third-annual class of Life Science Award recipients.

The Life Science Awards are meant to honor individual researchers and organizations for their innovation and breakthrough work in a specific area of the life sciences, including biology, biotechnology, genomics, neuroscience, and pharmacology. Parion is particularly focused on researching, developing and commercializing new therapies that improve and increase the quality of life and life expectancy of patients who suffer from innate mucosal surface defense deficiencies of the eye or airway, such as cystic fibrosis (CF).

“I am pleased to accept this award on behalf of our dedicated employees and founders. We truly appreciate the recognition and support as we continue to progress our innovative programs through the clinic and potentially to patients in need of new therapies,” stated the president and CEO of Parion Sciences, Paul Boucher, who was at the event to accept the award, according to a press release from the company.

“This year’s list of winners reflect the power, influence and intellect present in our communities within this sector,” added Bryan Michael Hamilton, publisher of the Triangle Business Journal. “In the Triangle, the life sciences industry continue to attract companies and individuals whose work and research are being monitored and revered across the globe. This sector continues to lead the Triangle’s economic resurgence.”

Parion is currently developing several pre-clinical and clinical investigational treatments for CF and other conditions with unique mechanisms of action and new therapeutic approaches. The company has received funding from both the National Institutes of Health (NIH) and the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation (CFF.)

The company also recently announced that it is initiating enrollment of CF patients for its phase 2 clinical trial to evaluate the experimental therapy P-1037. The trial is called Clearing Lungs with ENaC inhibition in Cystic Fibrosis (CLEAN-CF) and is designed as a randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of P-1037 solution for inhalation in patients with CF, regardless of their genetic mutations.